Vascular Biogenics Ltd. Stock News

Vascular Biogenics' (VBLT) CEO Dror Harats on Q1 2021 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and -7.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (NASDAQ:VBLT) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.

TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the closing of its underwritten public offeri

TEL AVIV, Israel, April 08, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced that it intends to offer and sell ordinary sh

Investors getting ready for another busy day of trading need to make sure they know the biggest pre-market stock movers before markets open. The post Today's Biggest Pre-Market Stock Movers: 10 Top Ga

TEL AVIV, Israel, March 30, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it will host a virtual R&D Day for analysts and investors beginning at 10:00am ET on Tuesday,

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2020 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -15.38% and 2.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Vascular Biogenics (NASDAQ:VBLT) rose 8.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 6.25% over the past year to ($0.15), wh

Conference Call and Webcast at 8:30 a . m . EDT Today

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics Ltd (NASDAQ: VBLT) announced positive results of the pre-specified interim analysis of the Phase 3 OVAL study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistan

While doing some speculative biotech window shopping, I came across VBL Therapeutics sitting on the sub-$100M market cap shelf. After a quick inspection, I am heading to the checkout.